Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q3 EPS of ($0.57), $0.06 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $47.7 million versus the consensus estimate of $37.12 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.